Company ProfilePremium

ChoA Pharmaceutical Co., Ltd.

Company Profile Analysis

Ticker: 034940.KQ조아제약 주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
ChoA Pharmaceutical Co., Ltd. - Company showcase

Year Founded & Workforce

1988

275 Employees

ChoA Pharmaceutical Co., Ltd. logo

ChoA Pharmaceutical Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

ChoA Pharmaceutical Co., Ltd. Overview

ChoA Pharmaceutical is a small, family-controlled Korean consumer-health manufacturer built on pharmacy-channel over-the-counter (OTC) medicines and health functional foods. It was founded in 1988 by Cho Won-ki, a pharmacist who had run a pharmacy for two decades before he acquired Samkang Pharmaceutical. Its identity rests on drinkable ampoule formats: it introduced Korea's first "double-neck" ampoule in 1995 and today makes about 200 medicines and health foods, including some 30 ampoule products such as Hepos/Hepatos (liver), Fematin (anaemia), Joa Viton (memory/endurance) and the Jalkton children's nutrition line. The model favours pharmacist education and direct pharmacy trade over mass advertising, supported by the affiliated Medipharm chain. Exports reach about 23 countries, led by Southeast Asia. Since 2019 the company has posted seven straight years of operating losses. Its equity has eroded close to share capital, and in 2026 it consolidated shares 5:1 to avoid new KOSDAQ "penny stock" delisting rules. By Q2 2026 it was near operating breakeven, helped by exports.


What the company does

ChoA manufactures and sells finished-dose medicines and consumer health products, mainly in Korea. Morningstar's profile lists treatments for diarrhoea, duodenal and gastric ulcer, gastritis, cough and cold, plus nutrition products, health drinks and mixed drinks for children. The company says its range covers general and specialised medicines, health supplements and pet products, aimed at children, women and the elderly (company profile via Datanyze).

Its core technical competence is liquid oral dosage in single-dose ampoules. The company states it produces about 200 medicines and health foods, including about 30 drinkable ampoule products such as Hepos, Fematin, Vasoclean and Mabis (company "About CHO-A" page). In 2022 it developed and patented a polypropylene ampoule, "CHO-A Safeasy". Patents were filed in 12 overseas jurisdictions, with commercial production from May 2023 (Hankyung, Aug 2022; company history).

Business and revenue model

Revenue componentDescriptionEvidence
Own-manufactured products (제품)OTC medicines, health functional foods, children's drinks and ampoule products made at Haman81% of revenue in Q2 2026 (Butler, from DART)
Merchandise (상품)In-licensed or purchased-for-resale products, e.g. Liposome Vitamin C 1000, sold under exclusive Korean distribution from Cure Support (Netherlands)19% of revenue in Q2 2026 (Butler); Dealsite, 4 Aug 2026
Product exportsOwn products shipped to about 23 countries15.5% of H1 2026 revenue (DailyPharm, 14 Sep 2026)
Contract manufacturing (CMO/OEM)Third-party manufacturing, especially ampoulesNamed as one of four 2026 core strategies (DailyPharm, Feb 2026); revenue not separately disclosed
E-commerce / home-shoppingHealth functional foods sold through partners on TV home-shopping and onlineMedigate/Hankyung, Aug 2022; "e-commerce channel diversification" is a 2026 strategy
Animal healthAnimal medicines and supplements; business purpose added at the March 2024 AGM; launched 2025Dealsite, Mar 2024 / Apr 2025; Kormedi, Feb 2026

The revenue model is entirely product sales. There is no subscription or recurring licensing revenue.

Value-chain position and customers

ChoA sits in finished-dose formulation, manufacturing and branded distribution. It buys active pharmaceutical ingredients (APIs) and excipients externally; the 2024–25 Galeo stock-out was traced to a process problem with a European API supplier (DailyPharm, Mar 2025). Domestic customers are mainly community pharmacies, served through direct trade. The company says it holds to direct dealing for OTC items, and has ties with Medipharm, a chain of about 1,000 pharmacies (DailyPharm, 2017). Some prescription (ETC) items are made by contract manufacturers and sold through wholesalers (DailyPharm, 2017). Overseas customers are distributors and importers in Southeast Asia, China, the US, Central Asia, Latin America and Africa.

One aggregator (Bullstory) describes a high share of hospital injectables and prescription drugs. Company statements and trade press consistently describe an OTC-centred model, and the company itself said in 2011 that it had no prescription drugs. Bullstory's characterisation is treated as inaccurate.

Company's own description

In its FAQ the company says it wants people everywhere to receive quality treatment regardless of status or location. Its mission is to deliver good-quality drugs at a fair price, working with reliable manufacturers, distributors and wholesalers, under the motto "Keep people happy and healthy, far away from diseases." It also states that all its facilities are located in South Korea. In explaining what sets it apart, it cites an indirect marketing approach that educates pharmacists and doctors rather than relying on mass advertising (company FAQ).

Independent characterisation

ChoA is a micro-cap, legacy pharmacy-OTC house. Its brands are well known (sports sponsorship, notably the long-running CHO-A Pharm Professional Baseball Award), but none of its products has reached the KRW 10 bn "leading OTC" scale. In 2017 management itself said it lacked a KRW 10 bn+ product (DailyPharm, 2017).

Its cost structure is poorly matched to its revenue base. SG&A was about 49% of revenue in 2024, and cost of sales plus SG&A exceeded revenue by 15% (Dealsite, Apr 2025). The many-products, small-batch manufacturing model is exposed to raw-material inflation, generic competition and Korean drug-price cuts. Management named these factors in explaining its 2025 results (Kormedi, Feb 2026).

The 2026 turnaround rests on three things: export growth (Southeast Asia, Latin America, Africa), deep SG&A cuts, and capital-markets measures to stay listed. It is real but early, and the improvement is two quarters old.

Strategy

Stated strategy

January 2026 New Year address (Vice Chairman Cho Sung-hwan): Restructuring is the top priority, pursued through four core strategies: (1) stronger pharmacist partnerships, (2) export expansion, (3) upgrading the CMO business, and (4) diversifying e-commerce channels (DailyPharm, Feb 2026). He also said growth would come from developing good medicines and opening new markets, with 2026 meant as the starting point of a real rebound (Kormedi, Feb 2026).

2026 roadmap (set early 2026): Fostering new businesses, diversifying distribution channels, raising brand value, strengthening digital marketing, and focusing H2 2026 on corporate value enhancement (SBS Biz; Hankyung, Jul 2026).

FY2023 annual report plan: Revive domestic sales, adjust cost ratios, pursue overseas business aggressively and develop new revenue sources (DailyPharm, Mar 2024).

Initiatives announced in the last 24 months

InitiativeTimingDetail / targetsStatusSource
Animal health entryPurpose added Mar 2024; launch 2025Animal medicines, feed and pet supplies; trademarks registeredLaunched; growth described as slowDealsite; Kormedi (Feb 2026)
Newhem iron-syrup export programme2026–2027KRW 2.2 bn across 6 countries in 2026; KRW 2.5 bn across 7 countries in 2027 (from KRW 0.7 bn across 4 in 2023)In progressSBS Biz; Hankyung
Latin America and Africa expansionMar 2026 onwardGuatemala (Hepatos, Elas-A); DR CongoIn progressDailyPharm; SBS Biz
Cost restructuring2,026H1 SG&A -12.8%; salaries -13.2%; advertising -70.7%Delivered in H1DailyPharm (Sep 2026)
5:1 share consolidationAnnounced Jun 2026; approved 6 Jul 2026; effective 27 Aug 2026Lift the share price above KRW 1,000; the company also cites a suitable share float and price stabilityCompletedSBS Biz; Daum/Newsis; DailyPharm
In-licensed premium supplementsJul 2026Exclusive Korean sale of Liposome Vitamin C 1000Launched; strong first weekDealsite (Aug 2026)
Land revaluationH1 2026About KRW 10.1 bn revaluation surplus added to equityBookedDailyPharm (Sep 2026)
Wastewater remediation2,025Facility upgrades and external self-testing; resumption of productionCompletedDailyPharm (Jan 2025); TheVC

Guidance and medium-term targets

No formal revenue or margin guidance was found for 2026–2027 beyond the Newhem export targets. Historical guidance has been unreliable: in 2022 the company targeted KRW 70 bn revenue and an operating profit, and delivered KRW 68.9 bn revenue with an operating loss of KRW 0.5 bn (Hankyung, Aug 2022). In 2017 it targeted KRW 60 bn revenue (DailyPharm, 2017). No ESG or sustainability targets are publicly disclosed.

Products & Services

ChoA's catalogue runs to about 200 SKUs. The items below are those individually documented in public sources. Pricing is not publicly disclosed for any item.

OTC medicines (pharmacy channel)

ProductCategory / descriptionTarget customerLaunch / statusKey factsSource
Joa Viton (조아바이톤)OTC aimed at memory improvement and enduranceAdults, students, elderlyLong-standingSales rose about 65% in 2010 to nearly KRW 6 bn; weaker sales in H1 2024eToday (2011); Bizwatch (2024)
Fematin (훼마틴)Haematinic (anaemia) ampouleWomen, pregnant womenLong-standing; flagship ampoule+24.1% in 2010; weaker in H1 2024eToday (2011); company site
Hepos Syrup (헤포스시럽)Ampoule liver drug made under Laphal technical cooperation; 30-ampoule and 4-ampoule packsAdultsLaunched Jul 2007Supplied mainly through Medipharm pharmacies at launchDailyPharm (2007)
Hepatos Syrup (헤파토스시럽)Liver-function agentAdults (drinking occasions)CurrentSales up more than 40% QoQ in Q2 2022; exported to Guatemala from Mar 2026Hankyung/Medigate (2022); DailyPharm (2026)
Galeo (가레오) liquid and soft capsulesDHBE (dihydroxydibutylether), a choleretic/digestive agentAdults with dyspepsiaApproved 1999Sales KRW 2.4 bn (2020), 1.6–1.8 bn (2021–23) and 0.48 bn (2024) during a stock-out that began mid-2024; MFDS clinical re-evaluation narrows the dose to 0.5 g three times a dayDailyPharm (Mar 2025; Sep 2024)
Uranitin solution (우라니틴액)L-ornithine-L-aspartate single-ingredient liquid (20 mL × 20 ampoules)Adults (hangover, fatty liver)Jul 2007Described at launch as the only domestically produced LOLA single-ingredient liquidDailyPharm (2007)
Elas-A solution (엘라스에이액)OTC liquidAdultsCurrentExported to Guatemala from Mar 2026DailyPharm (Sep 2026)
Newhem Syrup / Newhem Forte Syrup (뉴헴시럽 / 뉴헴포르테시럽)Iron supplements for iron-deficiency anaemiaEmerging markets: Africa and Southeast AsiaCurrentExports about KRW 0.7 bn across 4 countries (2023); target KRW 2.2 bn across 6 countries (2026) and KRW 2.5 bn across 7 (2027)SBS Biz; Hankyung (Jul 2026)
Naspen Syrup (나스펜시럽)Squeeze-pack children's fever and pain relieverChildrenRecentListed in DailyPharm related coverageDailyPharm
Choeun-i (조은아이)OTC (eye health per brand naming)AdultsCurrentNamed among key brandsDailyPharm (Mar 2024)
Vasoclean, MabisDrinkable ampoule productsAdultsCurrentNamed by the company among its 30 ampoule productsCompany "About" page
Others (company list, older translation)Vita Crayon Plus chewable tablets, nasal liquid, Eleanor Men's syrup and othersVariousVariousMachine-translated company list; names partly garbledHealthManagement.org listing

Children's nutrition and health functional foods

ProductDescriptionMarketLaunchKey factsSource
Jalkton (잘크톤) familyChildren's nutrition and health drink lineKoreaAbout 2006 (20th anniversary in 2026)Cumulative sales above 10.45 million units by end-June 2026; +16% in Q2 2022; weaker in H1 2024Hankyung (Jul 2026); Medigate (2022)
Jalkton step1Children's nutrition supplementIndonesiaFeb 2021Export line extensionCompany history
Jalkton Dino KidsChildren's nutrition supplementUzbekistanAug 2025Central Asia entryCompany history
Smart Dino / Long DinoChildren's drinksVietnamAug 2016Vietnam-specific linesCompany history
Licensed-character children's drinkChildren's drink using a licensed cartoon franchiseKoreaAnnounced 2022—Hankyung (Aug 2022)
Liposome Vitamin C 1000Liposomal vitamin C, 1,000 mg per sachet; exclusive Korean distribution of a Cure Support (Netherlands) productAdultsLate Jul 20268,000 boxes (240,000 sachets) sold in the first weekDealsite (4 Aug 2026)
Home-shopping/online health foods3–4 products prepared for home shopping in H2 2022, targeting about KRW 5 bnKorea2,022Partner-led distributionHankyung (Aug 2022)
Dunggule 9水Solomon's-seal tea beverageKoreaMay 2007Early diversification into beverageseToday (2007)

Platforms, services and new businesses

OfferingDescriptionStatusSource
CHO-A Safeasy AmpoulePolypropylene single-dose ampoule developed over about four years. The company says it releases no environmental hormones. Patented in Korea, with filings in 12 countries including the US, EU, Japan and China.Commercial production from May 2023; positioned for own products and OEMHankyung (Aug 2022); company history
Contract manufacturing (CMO)Formulation-to-manufacture services; the company cites expertise from early formulation to GMP scale-up and distribution2026 strategic priority ("CMO upgrade")Company FAQ; DailyPharm (Feb 2026)
Animal healthAnimal medicines and supplements; trademarks registeredLaunched 2025; product brand and sales not publicly disclosedDealsite; Kormedi
Masks (OEM)COVID-era masks via OEM, not own production2,020Dealsite (Feb 2020)

Financial Narrative

Income statement

Sources: revenue, operating income, net income and operating cash flow from OpenDART (consolidated) via Bullstory and Butler. SG&A, personnel, advertising and the cost ratio are from Dealsite (Apr 2025). FY2024 gross profit is derived here: 115.4% × 62.7 = KRW 72.4 bn total costs, less KRW 30.8 bn SG&A, gives about 41.6 bn COGS and about 21.1 bn gross profit. FY2023 advertising is derived from the stated +149.7% increase to KRW 2.3 bn.

Margins and growth

All margins are calculated here from the figures in 6.1; FY2024 gross margin is derived. Bullstory independently reports net margins of -14.0%, 0.7%, -17.7%, -16.2% and -12.4%, consistent within rounding.

Revenue CAGR: FY2021–FY2025 about +0.7% a year. From the FY2022 peak to FY2025 about -4.9% a year. Both calculated here.

Interim trend

Sources: The Fact (May 2024); Bizwatch (Aug 2024); DailyPharm (Nov 2025; 14 Sep 2026). Q1 2025 and Q1 2026 revenue and net income are derived as H1 less Q2. Q1 2026 operating loss of KRW 1.12 bn is as reported by DailyPharm; unips cites Q1 2026 revenue of about KRW 14.7 bn, consistent with the derivation.

H1 2026 cost detail (DailyPharm). Gross profit rose 6.7%. SG&A fell 12.8%, with salaries down 13.2% (KRW 6.4 bn to 5.6 bn) and advertising down 70.7% (KRW 1.0 bn to 0.3 bn). Gross margin was stable at about 36.7%, calculated here. The swing to profit came almost entirely from opex.

Balance sheet

Sources: Kormedi KRX notice (FY2025 assets, liabilities, equity); DailyPharm (Nov 2025; Sep 2026); Dealsite (Apr 2025). Equity of KRW 28.5 bn per Dealsite versus 28.6 bn per DailyPharm is a rounding difference. Share capital is assumed constant at about KRW 15.5 bn; pre-2023 values are not separately verified. The ratio row is calculated here.

Interim data points.

Q3 2025: equity KRW 24.4 bn; accumulated deficit KRW 51.6 bn (DailyPharm, Nov 2025).

30 Jun 2026: equity KRW 32.1 bn, including about KRW 10.1 bn of land revaluation surplus. Total borrowings KRW 24.54 bn. Inventory KRW 10.85 bn. The "capital procurement ratio" (borrowings relative to total capital) fell from 51.0% to 40.9% (DailyPharm, 14 Sep 2026).

End-2023: cash about KRW 1.9 bn (Dealsite headline, Mar 2024).

Net debt. About KRW 23 bn at end-2025 if cash was on the order of KRW 2 bn.

Cash flow

Source: OpenDART via Bullstory. No dividends since 2001 (DailyPharm, Dec 2025). No buyback programme was found in the period reviewed.

Ratios

Calculations by the analyst. FY2024 ROE uses average equity of (38.8 + 28.5) / 2. Stockhub reports a TTM ROE of -28.64%, consistent. Current ratio, ROIC, interest coverage, net debt/EBITDA, asset turnover and the cash conversion cycle cannot be computed reliably from verified data and are not publicly disclosed in the sources reviewed. Interest coverage is negative: operating income has been below zero every year since 2019.

Commentary on trends, inflections and drivers

Revenue. Revenue peaked at KRW 68.9 bn in 2022, a COVID-reopening rebound. The company tied that year's demand to the end of social-distancing rules: Hepatos rose with the return of social drinking and Jalkton with heightened health concern. Revenue then fell to KRW 59.3 bn in 2025, roughly back to 2018 levels (KRW 63.1 bn in 2018). Management cites lower domestic sales, weaker overseas sales in 2023, rising raw-material costs, generic competition and drug-price cuts (DailyPharm, Mar 2024; Kormedi, Feb 2026). Two specific shocks hit 2024–25: the Galeo stock-out, which cut a KRW 1.6–2.4 bn product to KRW 0.48 bn, and the Haman wastewater shutdown from 24 Jan 2025.

Profitability. Operating losses have run for seven consecutive years (2019–2025). The cumulative operating loss is about KRW 32.7 bn (Kormedi). Cost of sales plus SG&A rose from 100.7% of revenue in 2022 to 115.4% in 2024. Personnel costs were about half of SG&A, and advertising more than doubled in 2024 (Dealsite).

Inflection. The 2026 inflection comes from cost cuts rather than gross-margin expansion. Gross margin was flat; SG&A fell 12.8%. Q2 2026 operating loss was only KRW 23 million, and H1 2026 net income was KRW 0.23 bn, versus a KRW 3.78 bn loss in H1 2025.

Balance sheet. Equity fell from KRW 38.8 bn (2023) to 21.8 bn (2025), only about 1.4 times share capital. That raised the prospect of partial capital impairment (부분자본잠식) within one to two years at 2024 loss rates (Dealsite, Apr 2025). The mid-2026 land revaluation, adding about KRW 10.1 bn to equity, is non-cash and does not reflect operating improvement. DailyPharm explicitly cautions that it does not represent earnings-driven repair.

Cash. Operating cash flow has been negative every year from 2021 to 2025, so the business has been funded by borrowings, which stood at about KRW 25 bn.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipStakeActivitySource

ChoA Pharmaceutical Co., Ltd.

Listed parent

—

OTC/health-food manufacturing and sales

—

Medipharm (메디팜)

Affiliate/subsidiary

49.06%

Pharmacy franchise and drug sales; about 1,000 chain pharmacies (2017)

Dealsite; DailyPharm (2017)

IB Smart (아이비스마트)

Subsidiary

93.81%

Sports facility operation. ChoA bought 33,334 more shares for KRW 0.4 bn in early 2024.

Dealsite; Bizwatch (Aug 2024)

Vietnam subsidiary

Subsidiary

100%

Market presence in Vietnam (HCMC office since 2016)

Dealsite; company history

Panbiotech (팬바이오텍)

Former investee

Exited May 2024

Biotech affiliate; investment recovered

Bizwatch (Aug 2024)

Revenue by Segment and Revenue by Segment (%)

MetricFY2021FY2022FY2023FY2024FY2025

Total revenue (KRW Bn)

57.668.963.062.759.3

Product exports (KRW Bn)

———6.8315.840

Revenue excluding product exports (KRW Bn, derived)

———55.86953.460

Product exports share of revenue (%, derived)

———10.99.8

Revenue by Segment

Metric (half-year)H1 2023H1 2024H1 2025H1 2026

Domestic revenue (KRW Bn)

22.120.1——

Product exports (KRW Bn)

——2.6064.641

Product revenue, own-manufactured (KRW Bn)

——22.0624.00

Total revenue (KRW Bn)

32.430.528.01529.866

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

57.668.963.062.759.3

Revenue growth YoY (%)

—19.6-8.6-0.5-5.4

Gross profit (KRW Bn)

———21.1—

Operating income (KRW Bn)

-7.0-0.5-6.8-9.6-6.6

Net income (KRW Bn)

-8.00.5-11.1-10.2-7.4

Operating cash flow (KRW Bn)

-1.5-1.4-1.5-4.5-4.2

SG&A (KRW Bn)

———30.8—

Personnel cost in SG&A (KRW Bn)

———15.3—

Advertising expense (KRW Bn)

——0.922.3—

Cost of sales plus SG&A as % of revenue

—100.7110.9115.4—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

———33.6—

Operating margin (%)

-12.2-0.7-10.8-15.3-11.1

Net margin (%)

-13.90.7-17.6-16.3-12.5

SG&A as % of revenue

———49.2—

OCF as % of revenue

-2.6-2.0-2.4-7.2-7.1

Income Statement

MetricQ1 2024H1 2024Q1 2025Q2 2025H1 20259M 2025Q1 2026Q2 2026H1 2026

Revenue (KRW Bn)

14.730.514.37513.64028.015—14.68415.18229.866

Operating income (KRW Bn)

-1.4-3.5-2.106-1.503-3.609-5.1-1.120-0.023-1.143

Net income (KRW Bn)

-1.37-3.2——-3.781—-0.1500.3770.227

Gross profit (KRW Bn)

————10.282———10.973

SG&A (KRW Bn)

————13.891———12.116

Balance Sheet and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (KRW Bn)

————64.7

Total liabilities (KRW Bn)

————42.9

Total equity (KRW Bn)

——38.828.521.8

Share capital (KRW Bn)

15.515.515.515.515.5

Accumulated deficit (KRW Bn)

——38.247.8—

Total borrowings (KRW Bn)

————24.98

Inventory (KRW Bn)

————11.72

Equity-to-share-capital ratio (x)

——2.501.841.41

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Bn)

-1.5-1.4-1.5-4.5-4.2

Dividends paid (KRW Bn)

00000

Share buybacks (KRW Bn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2024FY2025

ROE (%, average equity)

-30.4-29.4

ROA (%, period-end assets)

—-11.4

Liabilities to equity (%)

—196.8

Borrowings to equity (x)

—1.15

Revenue by Region and Region Margins & Growth (%)

MetricFY2023FY2024FY2025

Product exports (KRW Bn)

—6.8315.840

Product exports YoY growth (%)

——-14.5

Newhem series exports (KRW Bn)

0.7——

Revenue by Region and Revenue by Region (%)

MetricH1 2025H1 2026

Product exports (KRW Bn)

2.6064.641

Product exports share of revenue (%)

9.315.5

Country / Region Details

Country / regionProductsDateSource

Vietnam

Ampoules (since 1995); Smart Dino and Long Dino (2016); HCMC office (2016)

1995 onward

Company history

Indonesia

Jalkton step1

Feb 2021

Company history

Uzbekistan

Jalkton Dino Kids

Aug 2025

Company history

Guatemala

Hepatos Syrup, Elas-A solution

Mar 2026

DailyPharm (Sep 2026)

DR Congo

Export network extension (Newhem iron syrups targeted at Africa)

2026

SBS Biz; Hankyung (Jul 2026)

Myanmar, Cambodia, China, US

Various

Ongoing

DailyPharm (Sep 2026)

Middle East

Exhibited at Arab Health Dubai

Feb 2020

Company history

Japan

Exhibited at ifia / HFE Japan

May 2025

Company history

Share Price History

DatePrice (KRW)Market cap (KRW Bn)Source

26 Aug 2020

Peak period

205.7

DailyPharm (Mar 2024)

2019 (gift date)

3,700—

Dealsite (Apr 2025)

Early Feb 2020

4,100 (after a spike to about 5,000)

—

Dealsite (Feb 2020)

Mar 2024

—

About 50 (KRW 50–60 bn range)

DailyPharm (Mar 2024)

1 Apr 2025

995 (52-week high 1,833)

—

Dealsite (Apr 2025)

28 Nov 2025

99730.9

DailyPharm (Dec 2025)

19 Feb 2026

1,01131.3

DailyPharm (Feb 2026)

20 Feb 2026

99730.9

Kormedi

Jun 2026

About 1,000 range, with limit-up spikes

30+

DailyPharm (Jun 2026)

~8 Jul 2026

568 (52-week range 498–1,420)

17.6

Stockhub

23 Jul 2026

606—

Bullstory

31 Jul 2026

585 (last pre-halt close)

About 18.1

Kormedi; Bullstory

Valuation Multiples

MultipleChoABasis / source

P/E

Not meaningful (loss-making on a trailing basis)

Stockhub; Butler

P/B

0.48 (Butler, date not stated); 0.77 (Stockhub, July 2026)

Aggregators

EV/Sales

About 0.7x (estimate)

—

EV/EBITDA

Not meaningful (EBITDA not disclosed; operating income negative)

—

Capital Markets

ItemStatusSource

Analyst coverage and consensus

None (0 reports)

Stockhub

Dividend history

None since 2001; dividend yield not applicable

DailyPharm (Dec 2025); Butler

Buyback authorisation

None found; treasury share ratio not shown

Butler

Credit ratings (Moody's, S&P, Fitch)

Not rated

—

Debt maturity profile

Not publicly disclosed; total borrowings KRW 24.54 bn at 30 Jun 2026

DailyPharm (Sep 2026)

Listing thresholds

Market cap of KRW 20 bn now (about KRW 3,228 per share on 6.2 million shares); KRW 30 bn from Jul 2027 (about KRW 4,842)

DailyPharm (Sep 2026)

Analyst Conclusions

Management guidance and consensus

There is no formal guidance and no analyst consensus. Management's stated aims are:

  • delivering tangible operating results in H2 2026 to lift corporate and shareholder value (SBS Biz, Jul 2026);

  • Newhem exports of KRW 2.2 bn in 2026 and KRW 2.5 bn in 2027;

  • continued export growth to new countries.

On H1 trends, DailyPharm observes that FY2026 product exports could exceed both the 2025 total (KRW 5.84 bn) and the 2024 total (KRW 6.83 bn).

Bull case

  1. Operating breakeven is in sight. The Q2 2026 operating loss was only KRW 23 million on revenue of KRW 15.18 bn (+11.3%). Holding H1 2026's SG&A run-rate of about KRW 24 bn a year, against about KRW 30.8 bn in 2024, with a gross margin near 36.7%, implies breakeven at roughly KRW 66 bn of revenue, or lower with mix gains (estimate). Export momentum makes FY2027 profitability plausible.

  2. Exports are a real growth engine. H1 2026 product exports rose 78.1% and the export share reached 15.5%. Latin America, Africa and Central Asia registrations, together with emerging-market iron demand, extend a 30-year Southeast Asian franchise.

  3. Deep asset discount. At a P/B of about 0.5–0.8, on equity of KRW 32.1 bn after revaluation, and with no analyst coverage, a return to profit could re-rate the stock sharply. The consolidation removed the penny-stock overhang.

Bear case

  1. The balance sheet is fragile and the repair is cosmetic. About KRW 10.1 bn of the H1 2026 equity increase is land revaluation. Operating cash flow was negative from 2021 to 2025 and borrowings are about KRW 25 bn. A rights issue, which would dilute existing holders, remains a live possibility (DailyPharm, Nov 2025).

  2. The core domestic franchise keeps shrinking. Domestic product sales are falling (DailyPharm, Jun 2026). Flagship brands weakened in 2024, and Galeo lost about 70% of its sales. Cost cutting, including a 70% cut in advertising, may accelerate brand erosion.

  3. Listing risk is postponed, not removed. The share price must reach about 5.5 times the pre-consolidation-equivalent level to clear the KRW 20 bn market-cap threshold, and more to clear KRW 30 bn from July 2027. One more operational shock (environmental, API supply or price cuts) could reverse the progress, given single-plant concentration.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhat to watch
Q3 2026 quarterly reportBy mid-Nov 2026First quarterly operating profit? Export run-rate; SG&A discipline
FY2026 preliminary and annual resultsFeb–Mar 2027End of the seven-year operating-loss streak; operating cash flow sign
Market cap against the KRW 20 bn and KRW 30 bn thresholdsContinuous; KRW 30 bn rule from Jul 2027Price above about KRW 3,228 and KRW 4,842 on the consolidated basis
Newhem export deliveryFY2026Against the KRW 2.2 bn and six-country target
Capital raisingAny timeRights issue, CB issue or asset sales
Galeo re-evaluation outcome and supply2026–2027Product continuation or withdrawal
Succession and share transfersAny timeGifts from the founder (born 1940) to his sons
Environmental compliance at HamanOngoingAny repeat violation
Animal health and CMO revenue disclosureFY2026 annual reportEvidence the new businesses have scale

Analyst verdict

ChoA Pharmaceutical is a turnaround candidate with a credible first leg and an unproven second. On the evidence of the H1 2026 report, management has stopped the bleeding where it was most controllable. SG&A fell by about KRW 1.8 bn in six months, and product exports nearly doubled, taking the Q2 operating loss to a rounding error and producing a half-year net profit for the first time since 2022. These are concrete improvements, not narrative. Yet they rest on a narrow base: two quarters of data, a gross margin that has not improved, and an advertising cut that buys margin today at the cost of brand equity tomorrow.

The structural problems remain. Revenue is still below its 2018 level. The Korean pharmacy OTC franchise that defined the company is shrinking. The company has no product of meaningful scale. Its single plant has already shown how quickly one compliance failure can threaten three-quarters of output. The balance sheet was repaired by revaluing land, not by earning money. Operating cash flow was negative in each of the five years to 2025, borrowings are about 1.1 times equity, and a capital raise cannot be ruled out.

The capital-markets overlay is decisive for equity holders. The 5:1 consolidation resolved the penny-stock test, but KOSDAQ's KRW 20 bn market-cap floor, rising to KRW 30 bn in July 2027, is a hard deadline. Only sustained profitability is likely to clear it.

On balance, ChoA is a high-risk, event-driven micro-cap whose investment case hinges almost entirely on converting Q2 2026's breakeven into consistent operating profit and positive operating cash flow by FY2027. The Q3 2026 report is the next decisive data point. Until then, the risk/reward is speculative, with a wide range of outcomes: a re-rating if export-led profitability holds, or dilution or delisting pressure if it does not.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleBornTenure / backgroundSource

Cho Won-ki (조원기)

Founder, Chairman, inside director; largest shareholder

1,940

Pharmacist who ran a pharmacy for about 20 years before acquiring Samkang in 1988; CEO until 2004; known for 20+ years of public health-education lectures

The Fact (2024); Dealsite; DailyPharm (2017)

Cho Sung-hwan (조성환)

Vice Chairman and co-CEO

1,970

CEO since 2004; Vice Chairman since 2017; also CEO of Medipharm. Historically led exports and biotech R&D; more recently leads marketing.

Dealsite; eToday (2014); The Fact (May 2024); DailyPharm (Nov 2025)

Cho Sung-bae (조성배)

President and co-CEO

1,972

Former Vice President of Medipharm; co-CEO since Nov 2014; historically led domestic pharmacy sales

eToday (2014); DailyPharm (2017); Dealsite

Major Shareholders

HolderShares (pre-consolidation, end-2024)Stake (%)Source

Cho Won-ki

3,508,84311.3

Dealsite (Apr 2025)

Cho Sung-hwan

1,893,1626.1

Dealsite (Apr 2025)

Cho Sung-bae

794,0002.6

Dealsite (Apr 2025)

Family total

6,196,00520.0

Calculated here

Competitive Landscape

Competitors by Segment

SegmentCompetitors (Korea unless noted)Overlap with ChoA

Pharmacy OTC: liver, digestive and ampoule drinks

Dong-A Pharmaceutical, Kwang Dong Pharmaceutical, Dongwha Pharm, Ildong Pharmaceutical, Daewoong Pharmaceutical, Samjin Pharm

Liver tonics, digestives, drinkable formats

Haematinics and vitamins

Yuhan Corp, Daewoong (Impactamin), Kyung Nam Pharm, Ildong

Fematin, Newhem, Liposome Vitamin C

Children's nutrition drinks and supplements

Dong-A, Ildong, Kwang Dong, Boryung Consumer Healthcare

Jalkton family

Small-cap KOSDAQ consumer pharma under listing pressure

Kyung Nam Pharm (also rallied on 2026 share-price-management news)

Similar investor profile

Animal health

Yuhan (Willowpet, Zedacure), Dong-A (Vetple), Daewoong (Daewoong Pet), Dongkook (Canidol), Jong Kun Dang Bio (Labivet), Yuyu Pharma, Kwang Dong, GC Cell

Late entrant (2025) into a crowded field

Contract manufacturing of liquids and ampoules

Domestic liquid-dose contract manufacturers (fragmented)

Safeasy-based OEM

Competitor Detail

MetricChoA (FY2025)

Revenue (KRW Bn)

59.3

Revenue growth (%)

-5.4

Operating margin (%)

-11.1

Company Snapshot

$41.7M

Revenue

275

Employees

1988

Founded

Seoul, South Korea

Headquarters

SWOT Analysis

Strengths

  • Ampoule technology leadership. First Korean double-neck ampoule (1995); about 30 ampoule SKUs; patented Safeasy PP ampoule, in production since May 2023 with filings in 12 countries.
  • Brand longevity. Jalkton reached 10.45 million cumulative units by June 2026, in its 20th year (Hankyung, Jul 2026).
  • Export platform. About 23 countries and about 150 SKUs. H1 2026 product exports rose 78.1% to KRW 4.64 bn (DailyPharm, Sep 2026).
  • Demonstrated cost flexibility. H1 2026 SG&A fell 12.8%, salaries 13.2% and advertising 70.7%, bringing Q2 operating loss to KRW 23 million.
  • Pharmacy channel ties. Direct OTC trade and the affiliated Medipharm chain of about 1,000 pharmacies (DailyPharm, 2017).
  • Hard-asset backing. A land revaluation in 2026 added about KRW 10.1 bn to equity, and P/B ranges from about 0.5 to 0.8 (Butler; Stockhub). Asset value exceeds market value.

Weaknesses

  • Chronic losses. Seven straight operating-loss years, about KRW 32.7 bn cumulative (Kormedi).
  • Bloated cost base. SG&A was 49.2% of revenue in 2024, and cost of sales plus SG&A reached 115.4% (Dealsite).
  • Eroding equity. Equity fell from KRW 38.8 bn (2023) to KRW 21.8 bn (2025), against KRW 15.5 bn of share capital.
  • Negative operating cash flow in each year from 2021 to 2025 (KRW -4.5 bn in 2024; -4.2 bn in 2025).
  • Single-plant concentration. The Haman lines account for KRW 47.0 bn, or 74.7% of revenue, and were shut from January 2025 (Kormedi).
  • No KRW 10 bn product, as acknowledged by management (DailyPharm, 2017); the Galeo stock-out cut that product's sales about 70%.

Opportunities

  • Emerging-market iron products. Newhem targets KRW 2.2 bn (2026) and KRW 2.5 bn (2027), from KRW 0.7 bn in 2023.
  • Latin America and Africa entry. Guatemala (Mar 2026) and DR Congo (2026) open new registration pipelines.
  • CMO monetisation of Safeasy ampoules, a 2026 core strategy.
  • Premium in-licensed supplements. Liposome Vitamin C sold 8,000 boxes in its first week (Dealsite).
  • Pet health market growth. Korea's pet market is projected to reach KRW 15 tn by 2027.
  • Operating breakeven. Q2 2026 was near breakeven; a full-year operating profit would end the loss streak and could re-rate a stock with no analyst coverage.

Threats

  • Delisting risk. The share price must reach about KRW 3,228 to clear the KRW 20 bn market-cap threshold, and about KRW 4,842 for the KRW 30 bn threshold from July 2027 (DailyPharm, Sep 2026).
  • Capital impairment. At 2024 loss rates, partial impairment was projected within one to two years (Dealsite, Apr 2025). The revaluation reprieve is non-recurring.
  • Regulatory pressure on legacy OTCs. The Galeo clinical re-evaluation could restrict or remove the product.
  • Environmental compliance. A repeat wastewater violation could halt production again under agro-complex standards.
  • Competition. Large pharma groups (Yuhan, Dong-A, Daewoong) already dominate pet health, and global firms reportedly hold about 80% of Korean pet drugs.
  • Input-cost inflation and drug-price cuts compress margins in many-SKU, small-batch production (Kormedi, Feb 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
20 Aug 2024H1 2024 revenue KRW 30.5 bn (-6.0%); operating loss KRW 3.5 bn; domestic sales KRW 20.1 bn BizwatchConfirms domestic erosion
8 Sep 2024MFDS publishes Galeo clinical re-evaluation draft DailyPharmRegulatory risk to a legacy product
10 Dec 2024Haman County notifies closure of the Haman wastewater facility, effective 24 Jan 2025 Kormedi; TheVCThreat to about 75% of revenue
23 Jan 2025Production halted from 24 Jan; detected level 0.021 ppm against a 0.01–0.011 ppm limit; safety stock maintained DailyPharmQ1 2025 sales hit
29 Mar 2025Galeo out of stock since mid-2024; sales down about 70% to KRW 0.48 bn DailyPharmAPI supply-chain fragility
31 Mar 2025FY2024 results: revenue KRW 62.7 bn, operating loss KRW 9.6 bn, net loss KRW 10.2 bn; impairment risk flagged DealsitePeak loss year
2 Apr 2025Press flags succession and gift timing at depressed share prices DealsiteGovernance overhang
–Haman plant production resumes TheVC (headline)Supply normalised
Q2 2025 (planned)Animal medicines launch Dealsite; The FactNew-business entry
May 2025Exhibits at ifia JAPAN / HFE JAPAN 2025 Company historyExport marketing
Aug 2025Launches Jalkton Dino Kids in Uzbekistan Company historyCentral Asia entry
21 Nov 20259M 2025 operating loss KRW 5.1 bn; equity KRW 24.4 bn; accumulated deficit KRW 51.6 bn DailyPharmImpairment proximity
28 Nov 2025Share closes at KRW 997, below KRW 1,000; market cap KRW 30.9 bn DailyPharm (1 Dec 2025)Penny-stock status
Jan 2026Vice Chairman's New Year address sets the four core strategies DailyPharm (Feb 2026)Strategic reset
19 Feb 2026FY2025 preliminary results: revenue KRW 59.3 bn (-5.4%); operating loss KRW 6.6 bn Kormedi (Feb 2026)Seventh straight operating loss
19–20 Feb 2026Share at KRW 1,011, then KRW 997; market cap about KRW 31 bn against tightening listing thresholds DailyPharm (Feb 2026); KormediDelisting risk discourse
Feb 2026Financial Services Commission (FSC) announces KOSDAQ delisting reform for insolvent firms DailyPharm (Jun 2026)Regulatory pressure
Mar 2026First Latin American shipments (Guatemala) DailyPharm (Sep 2026)Export diversification
May 2026KRX approves the listing-rule amendment DailyPharm (Jun 2026)Penny-stock rule from July
May/Jun 2026Board decides the 5:1 share consolidation Stockhub (Edaily headline); Daum/NewsisListing defence
Jun 2026Shares hit limit-up on consecutive days after the consolidation news; another limit-up (+29.98%) during sector strength around BIO USA Daum/Newsis (23 Jun 2026); StockplusSpeculative trading
23–24 Jun 2026KRX inquiry on abnormal price movement; company replies there is no material undisclosed information Butler (disclosure list)Volatility
6 Jul 2026Extraordinary general meeting approves the consolidation SBS Biz; HankyungCorporate action
7 Jul 2026Company reports Jalkton cumulative sales of 10.45 million units and Newhem export targets Hankyung; Medipharm HealthInvestor messaging
Late Jul 2026Launches Liposome Vitamin C 1000; 8,000 boxes sold in the first week Dealsite (4 Aug 2026)New merchandise revenue
31 Jul 2026KRX notice of trading halt from 5 Aug 2026 for the consolidation; last close KRW 585 KormediCorporate action
14 Aug 2026H1 2026 report: revenue +6.6%; operating loss -68%; net profit KRW 0.23 bn Butler; DailyPharmTurnaround evidence
27 Aug 2026Trading resumes on a consolidated basis (6,195,965 shares) DailyPharm (14 Sep 2026)Penny-stock rule addressed
14 Sep 2026Press analysis: about KRW 3,228 per share needed for a KRW 20 bn market cap, and about KRW 4,842 for KRW 30 bn DailyPharmNext listing hurdle

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue rose from KRW 57.6 Bn in FY2021 to KRW 59.3 Bn in FY2025.
ChoA Pharmaceutical Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (KRW Bn)FY2021FY2022FY2023FY2024FY2025
Revenue57.668.96362.759.3
Gross profit———21.1—
Cost of sales plus SG&A as % of revenue—100.7110.9115.4—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. ChoA company history (EN) (choa.co.kr)
  2. ChoA "About CHO-A" (EN, mobile) (m.choa.co.kr)
  3. ChoA FAQs (m.choa.co.kr)
  4. DailyPharm, "조아, 손익분기점 눈앞…" (14 Sep 2026) (dailypharm.com)
  5. DailyPharm, "조아, 주가 1000원대 등락…" (25 Jun 2026) (dailypharm.com)
  6. DailyPharm, "조아제약, 주가 1000원선 붕괴 눈앞…" (20 Feb 2026) (m.dailypharm.com)
  7. DailyPharm, "'적자' 조아제약 동전주 전락…" (1 Dec 2025) (dailypharm.com)
  8. DailyPharm, "조아제약, '7년 적자·자본잠식' 위기…" (21 Nov 2025) (m.dailypharm.com)
  9. DailyPharm, "조아제약 가레오, 2년째 장기품절…" (29 Mar 2025) (m.dailypharm.com)
  10. DailyPharm, "'폐수처리 위반' 조아제약 공장…" (23 Jan 2025) (m.dailypharm.com)
  11. DailyPharm, "가레오 임상재평가 시안" (8 Sep 2024) (m.dailypharm.com)
  12. DailyPharm, "'매출 5년 전 회귀·5년 적자'…" (28 Mar 2024) (dailypharm.com)
  13. DailyPharm, "100억 리딩OTC 육성…" (6 Mar 2017) (dailypharm.com)
  14. DailyPharm, "헤포스시럽 출시" (8 Jul 2007) (m.dailypharm.com)
  15. Dealsite, "높은 원가율, 자본잠식 리스크" (2 Apr 2025) (dealsite.co.kr)
  16. Dealsite, "5년새 주가 70% 뚝…지분 승계" (4 Apr 2025) (dealsite.co.kr)
  17. Dealsite, "'현금 19억' 조아제약, 사업다각화" (6 Mar 2024) (dealsite.co.kr)
  18. Dealsite, ownership and succession (dealsite.co.kr)
  19. Dealsite, CB conversion (7 Feb 2020) (dealsite.co.kr)
  20. Dealsite, Liposome Vitamin C 1000 (4 Aug 2026) (dealsite.co.kr)
  21. Kormedi, trading halt / FY2025 financials (Aug 2026) (kormedi.com)
  22. Kormedi, FY2025 results and animal health (Feb 2026) (kormedi.com)
  23. Kormedi, Haman plant suspension (Dec 2024) (kormedi.com)
  24. SBS Biz, share consolidation approved (7 Jul 2026) (biz.sbs.co.kr)
  25. Hankyung, H2 growth strategy (7 Jul 2026) (hankyung.com)
  26. Hankyung, H1 2022 results and Safeasy (19 Aug 2022) (hankyung.com)
  27. Daum/Newsis, penny-stock rule and price management (23 Jun 2026) (v.daum.net)
  28. Bizwatch, H1 2024 results (20 Aug 2024) (news.bizwatch.co.kr)
  29. The Fact, Q1 2024 results (20 May 2024) (news.tf.co.kr)
  30. The Fact, pharma pet-market entry (11 Mar 2025) (news.tf.co.kr)
  31. eToday, co-CEO appointment (2014) (etoday.co.kr)
  32. eToday, 2010 results (2011) (etoday.co.kr)
  33. eToday, company profile (2007) (etoday.co.kr)
  34. Medigate News, H1 2022 results (medigatenews.com)
  35. Medical Times, animal-health entry (medicaltimes.com)
  36. Bullstory financials (OpenDART) (bullstory.io)
  37. Butler company page (OpenDART) (butler.works)
  38. Stockhub quote page (stockhub.kr)
  39. Morningstar profile (morningstar.com.au)
  40. Datanyze profile (datanyze.com)
  41. TheVC (Haman County, plant resumption headline) (thevc.kr)
  42. DailyVet, pet supplement market data (dailyvet.co.kr)
  43. Stockplus, limit-up report (newsroom.stockplus.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.